TY - JOUR
T1 - Blood pressure in chronic kidney disease
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Conference Participants
AU - Cheung, Alfred K.
AU - Chang, Tara I.
AU - Cushman, William C.
AU - Furth, Susan L.
AU - Ix, Joachim H.
AU - Pecoits-Filho, Roberto
AU - Perkovic, Vlado
AU - Sarnak, Mark J.
AU - Tobe, Sheldon W.
AU - Tomson, Charles R.V.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Mann, Johannes F.E.
AU - Bakris, George L.
AU - Damasceno, Albertino
AU - Dwyer, Jamie P.
AU - Fried, Linda F.
AU - Haynes, Richard
AU - Hirawa, Nobuhito
AU - Holdaas, Hallvard
AU - Ibrahim, Hassan N.
AU - Ingelfinger, Julie R.
AU - Iseki, Kunitoshi
AU - Khwaja, Arif
AU - Kimmel, Paul L.
AU - Kovesdy, Csaba P.
AU - Ku, Elaine
AU - Lerma, Edgar V.
AU - Luft, Friedrich C.
AU - Lv, Jicheng
AU - McFadden, Christopher B.
AU - Muntner, Paul
AU - Myers, Martin G.
AU - Navaneethan, Sankar D.
AU - Parati, Gianfranco
AU - Peixoto, Aldo J.
AU - Prasad, Ramesh
AU - Rahman, Mahboob
AU - Rocco, Michael V.
AU - Rodrigues, Cibele Isaac Saad
AU - Roger, Simon D.
AU - Stergiou, George S.
AU - Tomlinson, Laurie A.
AU - Tonelli, Marcello
AU - Toto, Robert D.
AU - Tsukamoto, Yusuke
AU - Walker, Robert
AU - Wang, Angela Yee Moon
AU - Wang, Jiguang
N1 - Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Akebia Therapeutics, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Pfizer, and Relypsa. We thank Jennifer King, PhD, for assistance with manuscript preparation.
Funding Information:
AKC declared having received consultancy fees from Boehringer Ingelheim and research support from the National Institutes of Health for SPRINT. TIC declared having received consultancy fees from Janssen Research and Development and Novo Nordisk; and research support from National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and Satellite Healthcare. WCC declared having received consultancy fees from Sanofi; and research support from Eli Lilly and Company, National Institutes of Health, and National Institute on Aging. SLF declared having received research support from National Institutes of Health. JHI declared having received research support from Baxter Healthcare. RP-F declared having received consultancy fees from Akebia Therapeutics, AstraZeneca, Fresenius Medical Care, and Novo Nordisk; speaker honoraria from Akebia Therapeutics, AstraZeneca, and Novo Nordisk; and research support from Fresenius Medical Care. MJS declared having received research support from Akebia Therapeutics (monies paid to institution), National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute on Aging. SWT declared having received research support from AbbVie and Bayer HealthCare; speaker honoraria from Bausch, Pfizer, and Servier; and research support from KMH Labs. DCW declared having received consultancy fees from Akebia Therapeutics, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia Therapeutics, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. JFEM declared having received consultancy fees from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Celgene, Fresenius Medical Care, Novo Nordisk, and Vifor Pharma; speaker honoraria from B. Braun, Eli Lilly and Company, Medice, Novo Nordisk, and Vifor Pharma; and research support from the European Union. All the other authors declared no competing interests.
Publisher Copyright:
© 2019 The Authors
PY - 2019/5
Y1 - 2019/5
N2 - In September 2017, KDIGO (Kidney Disease: Improving Global Outcomes) convened a Controversies Conference titled Blood Pressure in Chronic Kidney Disease (CKD). The purpose of the meeting was to consider which recommendations from the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD should be reevaluated based on new evidence from clinical trials. Participants included a multidisciplinary panel of clinical and scientific experts. Discussions focused on the optimal means for measuring blood pressure (BP) as well as managing BP in CKD patients. Consistent with the 2012 Guideline, the conference did not address BP management in patients on maintenance dialysis.
AB - In September 2017, KDIGO (Kidney Disease: Improving Global Outcomes) convened a Controversies Conference titled Blood Pressure in Chronic Kidney Disease (CKD). The purpose of the meeting was to consider which recommendations from the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD should be reevaluated based on new evidence from clinical trials. Participants included a multidisciplinary panel of clinical and scientific experts. Discussions focused on the optimal means for measuring blood pressure (BP) as well as managing BP in CKD patients. Consistent with the 2012 Guideline, the conference did not address BP management in patients on maintenance dialysis.
KW - blood pressure measurement
KW - blood pressure targets
KW - cardiovascular events
KW - guideline
KW - treatment threshold
UR - http://www.scopus.com/inward/record.url?scp=85064220125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064220125&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2018.12.025
DO - 10.1016/j.kint.2018.12.025
M3 - Article
C2 - 31010478
AN - SCOPUS:85064220125
SN - 0085-2538
VL - 95
SP - 1027
EP - 1036
JO - Kidney international
JF - Kidney international
IS - 5
ER -